Response to primary and booster vaccination with 10-valent pneumococcal nontypeable haemophilus influenzae protein D conjugate vaccine in Korean infants

Chang Hwi Kim, Jung Soo Kim, Sung Ho Cha, Kwang Nam Kim, Jong Duck Kim, Kyung Yil Lee, Hwang Min Kim, Jong Hyun Kim, Sang Hyuk, Jung Yun Hong, Su Eun Park, Yun Kyung Kim, Nam Hee Kim, Aurélie Fanic, Dorota Borys, Javier Ruiz-Guiñazù, Marta Moreira, Lode Schuerman, Kyung Hyo Kim

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: This randomized single-blind study in Korea evaluated noninferiority of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) versus the 7-valent pneumococcal conjugate vaccine (7vCRM) when both were coadministered with H. influenzae type b (Hib) conjugate vaccine, as opposed to coadministration with diphtheria-tetanus- acellular pertussis-based combination vaccines in previous studies. Methods: Infants received 3 primary doses at 2, 4, and 6 months and a booster dose at 12 to 18 months of PHiD-CV (N = 374) or 7vCRM (N = 129), both coadministered with Hib vaccine. Immune responses were measured 1 month postdose 3 and postbooster using 22F-inhibition enzyme-linked immunosorbent assay and functional opsonophagocytic activity assay. Results: PHiD-CV-induced antibody responses against each of the vaccine pneumococcal serotypes and protein D. Noninferiority to 7vCRM was demonstrated for all 10 PHiD-CV serotypes in terms of percentages of subjects reaching an antibody concentration 0.2 μg/mL after primary vaccination. Postprimary and postbooster, percentages of subjects with antibody concentration 0.2 μg/mL or opsonophagocytic activity titer 8 were generally consistent between groups for each pneumococcal serotype common to both vaccines. The safety and reactogenicity profiles of PHiD-CV and 7vCRM were generally comparable after both primary and booster vaccination. Conclusions: In this Korean study, 3-dose PHiD-CV priming followed by a booster dose was immunogenic for all 10 vaccine pneumococcal serotypes and protein D. Noninferiority to 7vCRM in terms of enzyme-linked immunosorbent assay threshold responses postpriming was demonstrated. The safety and reactogenicity profiles of both vaccines when coadministered with Hib vaccine were generally comparable.

Original languageEnglish
JournalPediatric Infectious Disease Journal
Volume30
Issue number12
DOIs
Publication statusPublished - 2011 Dec 1
Externally publishedYes

Fingerprint

Conjugate Vaccines
Vaccination
Haemophilus influenzae type b
Pneumococcal Vaccines
Haemophilus Vaccines
Vaccines
Enzyme-Linked Immunosorbent Assay
Single-Blind Method
Combined Vaccines
Safety
Diphtheria
Haemophilus influenzae glpQ protein
Antibodies
Whooping Cough
Tetanus
Korea
Antibody Formation
Proteins
Serogroup

Keywords

  • Haemophilus influenzae
  • immunogenicity
  • pneumococcal conjugate vaccine
  • Streptococcus pneumoniae

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Response to primary and booster vaccination with 10-valent pneumococcal nontypeable haemophilus influenzae protein D conjugate vaccine in Korean infants. / Kim, Chang Hwi; Kim, Jung Soo; Cha, Sung Ho; Kim, Kwang Nam; Kim, Jong Duck; Lee, Kyung Yil; Kim, Hwang Min; Kim, Jong Hyun; Hyuk, Sang; Hong, Jung Yun; Park, Su Eun; Kim, Yun Kyung; Kim, Nam Hee; Fanic, Aurélie; Borys, Dorota; Ruiz-Guiñazù, Javier; Moreira, Marta; Schuerman, Lode; Kim, Kyung Hyo.

In: Pediatric Infectious Disease Journal, Vol. 30, No. 12, 01.12.2011.

Research output: Contribution to journalArticle

Kim, CH, Kim, JS, Cha, SH, Kim, KN, Kim, JD, Lee, KY, Kim, HM, Kim, JH, Hyuk, S, Hong, JY, Park, SE, Kim, YK, Kim, NH, Fanic, A, Borys, D, Ruiz-Guiñazù, J, Moreira, M, Schuerman, L & Kim, KH 2011, 'Response to primary and booster vaccination with 10-valent pneumococcal nontypeable haemophilus influenzae protein D conjugate vaccine in Korean infants', Pediatric Infectious Disease Journal, vol. 30, no. 12. https://doi.org/10.1097/INF.0b013e31822a8541
Kim, Chang Hwi ; Kim, Jung Soo ; Cha, Sung Ho ; Kim, Kwang Nam ; Kim, Jong Duck ; Lee, Kyung Yil ; Kim, Hwang Min ; Kim, Jong Hyun ; Hyuk, Sang ; Hong, Jung Yun ; Park, Su Eun ; Kim, Yun Kyung ; Kim, Nam Hee ; Fanic, Aurélie ; Borys, Dorota ; Ruiz-Guiñazù, Javier ; Moreira, Marta ; Schuerman, Lode ; Kim, Kyung Hyo. / Response to primary and booster vaccination with 10-valent pneumococcal nontypeable haemophilus influenzae protein D conjugate vaccine in Korean infants. In: Pediatric Infectious Disease Journal. 2011 ; Vol. 30, No. 12.
@article{ca9b8dfa68ea4afea674a0b48b11cd13,
title = "Response to primary and booster vaccination with 10-valent pneumococcal nontypeable haemophilus influenzae protein D conjugate vaccine in Korean infants",
abstract = "Background: This randomized single-blind study in Korea evaluated noninferiority of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) versus the 7-valent pneumococcal conjugate vaccine (7vCRM) when both were coadministered with H. influenzae type b (Hib) conjugate vaccine, as opposed to coadministration with diphtheria-tetanus- acellular pertussis-based combination vaccines in previous studies. Methods: Infants received 3 primary doses at 2, 4, and 6 months and a booster dose at 12 to 18 months of PHiD-CV (N = 374) or 7vCRM (N = 129), both coadministered with Hib vaccine. Immune responses were measured 1 month postdose 3 and postbooster using 22F-inhibition enzyme-linked immunosorbent assay and functional opsonophagocytic activity assay. Results: PHiD-CV-induced antibody responses against each of the vaccine pneumococcal serotypes and protein D. Noninferiority to 7vCRM was demonstrated for all 10 PHiD-CV serotypes in terms of percentages of subjects reaching an antibody concentration 0.2 μg/mL after primary vaccination. Postprimary and postbooster, percentages of subjects with antibody concentration 0.2 μg/mL or opsonophagocytic activity titer 8 were generally consistent between groups for each pneumococcal serotype common to both vaccines. The safety and reactogenicity profiles of PHiD-CV and 7vCRM were generally comparable after both primary and booster vaccination. Conclusions: In this Korean study, 3-dose PHiD-CV priming followed by a booster dose was immunogenic for all 10 vaccine pneumococcal serotypes and protein D. Noninferiority to 7vCRM in terms of enzyme-linked immunosorbent assay threshold responses postpriming was demonstrated. The safety and reactogenicity profiles of both vaccines when coadministered with Hib vaccine were generally comparable.",
keywords = "Haemophilus influenzae, immunogenicity, pneumococcal conjugate vaccine, Streptococcus pneumoniae",
author = "Kim, {Chang Hwi} and Kim, {Jung Soo} and Cha, {Sung Ho} and Kim, {Kwang Nam} and Kim, {Jong Duck} and Lee, {Kyung Yil} and Kim, {Hwang Min} and Kim, {Jong Hyun} and Sang Hyuk and Hong, {Jung Yun} and Park, {Su Eun} and Kim, {Yun Kyung} and Kim, {Nam Hee} and Aur{\'e}lie Fanic and Dorota Borys and Javier Ruiz-Gui{\~n}az{\`u} and Marta Moreira and Lode Schuerman and Kim, {Kyung Hyo}",
year = "2011",
month = "12",
day = "1",
doi = "10.1097/INF.0b013e31822a8541",
language = "English",
volume = "30",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Response to primary and booster vaccination with 10-valent pneumococcal nontypeable haemophilus influenzae protein D conjugate vaccine in Korean infants

AU - Kim, Chang Hwi

AU - Kim, Jung Soo

AU - Cha, Sung Ho

AU - Kim, Kwang Nam

AU - Kim, Jong Duck

AU - Lee, Kyung Yil

AU - Kim, Hwang Min

AU - Kim, Jong Hyun

AU - Hyuk, Sang

AU - Hong, Jung Yun

AU - Park, Su Eun

AU - Kim, Yun Kyung

AU - Kim, Nam Hee

AU - Fanic, Aurélie

AU - Borys, Dorota

AU - Ruiz-Guiñazù, Javier

AU - Moreira, Marta

AU - Schuerman, Lode

AU - Kim, Kyung Hyo

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Background: This randomized single-blind study in Korea evaluated noninferiority of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) versus the 7-valent pneumococcal conjugate vaccine (7vCRM) when both were coadministered with H. influenzae type b (Hib) conjugate vaccine, as opposed to coadministration with diphtheria-tetanus- acellular pertussis-based combination vaccines in previous studies. Methods: Infants received 3 primary doses at 2, 4, and 6 months and a booster dose at 12 to 18 months of PHiD-CV (N = 374) or 7vCRM (N = 129), both coadministered with Hib vaccine. Immune responses were measured 1 month postdose 3 and postbooster using 22F-inhibition enzyme-linked immunosorbent assay and functional opsonophagocytic activity assay. Results: PHiD-CV-induced antibody responses against each of the vaccine pneumococcal serotypes and protein D. Noninferiority to 7vCRM was demonstrated for all 10 PHiD-CV serotypes in terms of percentages of subjects reaching an antibody concentration 0.2 μg/mL after primary vaccination. Postprimary and postbooster, percentages of subjects with antibody concentration 0.2 μg/mL or opsonophagocytic activity titer 8 were generally consistent between groups for each pneumococcal serotype common to both vaccines. The safety and reactogenicity profiles of PHiD-CV and 7vCRM were generally comparable after both primary and booster vaccination. Conclusions: In this Korean study, 3-dose PHiD-CV priming followed by a booster dose was immunogenic for all 10 vaccine pneumococcal serotypes and protein D. Noninferiority to 7vCRM in terms of enzyme-linked immunosorbent assay threshold responses postpriming was demonstrated. The safety and reactogenicity profiles of both vaccines when coadministered with Hib vaccine were generally comparable.

AB - Background: This randomized single-blind study in Korea evaluated noninferiority of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) versus the 7-valent pneumococcal conjugate vaccine (7vCRM) when both were coadministered with H. influenzae type b (Hib) conjugate vaccine, as opposed to coadministration with diphtheria-tetanus- acellular pertussis-based combination vaccines in previous studies. Methods: Infants received 3 primary doses at 2, 4, and 6 months and a booster dose at 12 to 18 months of PHiD-CV (N = 374) or 7vCRM (N = 129), both coadministered with Hib vaccine. Immune responses were measured 1 month postdose 3 and postbooster using 22F-inhibition enzyme-linked immunosorbent assay and functional opsonophagocytic activity assay. Results: PHiD-CV-induced antibody responses against each of the vaccine pneumococcal serotypes and protein D. Noninferiority to 7vCRM was demonstrated for all 10 PHiD-CV serotypes in terms of percentages of subjects reaching an antibody concentration 0.2 μg/mL after primary vaccination. Postprimary and postbooster, percentages of subjects with antibody concentration 0.2 μg/mL or opsonophagocytic activity titer 8 were generally consistent between groups for each pneumococcal serotype common to both vaccines. The safety and reactogenicity profiles of PHiD-CV and 7vCRM were generally comparable after both primary and booster vaccination. Conclusions: In this Korean study, 3-dose PHiD-CV priming followed by a booster dose was immunogenic for all 10 vaccine pneumococcal serotypes and protein D. Noninferiority to 7vCRM in terms of enzyme-linked immunosorbent assay threshold responses postpriming was demonstrated. The safety and reactogenicity profiles of both vaccines when coadministered with Hib vaccine were generally comparable.

KW - Haemophilus influenzae

KW - immunogenicity

KW - pneumococcal conjugate vaccine

KW - Streptococcus pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=81855221739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81855221739&partnerID=8YFLogxK

U2 - 10.1097/INF.0b013e31822a8541

DO - 10.1097/INF.0b013e31822a8541

M3 - Article

VL - 30

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 12

ER -